148 related articles for article (PubMed ID: 38267790)
1. Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.
Saadeddin A; Purohit V; Huh Y; Wong M; Maulny A; Dowty ME; Sagawa K
AAPS J; 2024 Jan; 26(1):17. PubMed ID: 38267790
[TBL] [Abstract][Full Text] [Related]
2. In Vitro In Vivo Extrapolation and Bioequivalence Prediction for Immediate-Release Capsules of Cefadroxil Based on a Physiologically-Based Pharmacokinetic ACAT Model.
Rahim N; Naqvi SBS
AAPS PharmSciTech; 2024 May; 25(5):100. PubMed ID: 38714602
[TBL] [Abstract][Full Text] [Related]
3. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.
Laisney M; Heimbach T; Mueller-Zsigmondy M; Blumenstein L; Costa R; Ji Y
J Pharm Sci; 2022 Jan; 111(1):274-284. PubMed ID: 34678270
[TBL] [Abstract][Full Text] [Related]
5. Efficient drug development of oseltamivir capsules based on process control, bioequivalence and PBPK modeling.
Medeiros JJS; Costa TM; Carmo MP; Nascimento DD; Lauro ENC; Oliveira CA; Duque MD; Prado LD
Drug Dev Ind Pharm; 2022 Apr; 48(4):146-157. PubMed ID: 35876070
[TBL] [Abstract][Full Text] [Related]
6. Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified-Release Dosage Form.
Purohit V; Sagawa K; Hsu HJ; Kushner J; Dowty ME; Tse S; Lin J; Blanchard A; Mukherjee A; Le V; Chang C
Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38797995
[TBL] [Abstract][Full Text] [Related]
7. Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development.
Wojciechowski J; S Purohit V; Huh Y; Banfield C; Nicholas T
Clin Pharmacokinet; 2023 Dec; 62(12):1765-1779. PubMed ID: 37917289
[TBL] [Abstract][Full Text] [Related]
8. Virtual Bioequivalence Assessment of Elagolix Formulations Using Physiologically Based Pharmacokinetic Modeling.
Mukherjee D; Chen MJ; Shao X; Ju TR; Shebley M; Marroum P
AAPS J; 2023 Mar; 25(3):30. PubMed ID: 36949256
[TBL] [Abstract][Full Text] [Related]
9. In vitro-In vivo Relationship and Bioequivalence Prediction for Modified-Release Capsules Based on a PBPK Absorption Model.
Jereb R; Opara J; Legen I; Petek B; Grabnar-Peklar D
AAPS PharmSciTech; 2019 Dec; 21(1):18. PubMed ID: 31820131
[TBL] [Abstract][Full Text] [Related]
10. LITFULO
Gupta AK; Ravi SP; Vincent K; Abramovits W
Skinmed; 2023; 21(6):434-438. PubMed ID: 38051245
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.
Wu D; Sanghavi M; Kollipara S; Ahmed T; Saini AK; Heimbach T
Pharm Res; 2023 Feb; 40(2):337-357. PubMed ID: 35840856
[TBL] [Abstract][Full Text] [Related]
12. Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs.
Yang B; Wu C; Ji B; Wu M; He Z; Shang L; Sun J
Asian J Pharm Sci; 2017 Jan; 12(1):98-104. PubMed ID: 32104318
[TBL] [Abstract][Full Text] [Related]
13. Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria.
Doki K; Darwich AS; Patel N; Rostami-Hodjegan A
Eur J Pharm Sci; 2017 Nov; 109():111-120. PubMed ID: 28774813
[TBL] [Abstract][Full Text] [Related]
14. Conjunction of semi-mechanistic in vitro-in vivo modeling and population pharmacokinetics as a tool for virtual bioequivalence analysis - a case study for a BCS class II drug.
Danielak D; Paszkowska J; Staniszewska M; Garbacz G; Terlecka A; Kubiak B; Romański M
Eur J Pharm Biopharm; 2023 May; 186():132-143. PubMed ID: 37015321
[TBL] [Abstract][Full Text] [Related]
15. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
16. Investigating the Impact of Drug Crystallinity in Amorphous Tacrolimus Capsules on Pharmacokinetics and Bioequivalence Using Discriminatory In Vitro Dissolution Testing and Physiologically Based Pharmacokinetic Modeling and Simulation.
Purohit HS; Trasi NS; Sun DD; Chow ECY; Wen H; Zhang X; Gao Y; Taylor LS
J Pharm Sci; 2018 May; 107(5):1330-1341. PubMed ID: 29289674
[TBL] [Abstract][Full Text] [Related]
17. Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling.
Bego M; Patel N; Cristofoletti R; Rostami-Hodjegan A
AAPS J; 2022 Jan; 24(1):21. PubMed ID: 34988679
[TBL] [Abstract][Full Text] [Related]
18. In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation.
Zhang F; Zhou Y; Wu N; Jia R; Liu A; Liu B; Zhou Z; Hu H; Han Z; Ye X; Ding Y; He Q; Wang H
Eur J Pharm Sci; 2021 Feb; 157():105618. PubMed ID: 33122011
[TBL] [Abstract][Full Text] [Related]
19. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E; Pavel AB; Diaz A; Zhang N; Del Duca E; Estrada Y; King B; Banerjee A; Banfield C; Cox LA; Dowty ME; Page K; Vincent MS; Zhang W; Zhu L; Peeva E
J Allergy Clin Immunol; 2022 Apr; 149(4):1318-1328. PubMed ID: 34863853
[TBL] [Abstract][Full Text] [Related]
20. Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in Regulatory Perspective: Application to Supersede f2, Enabling Biowaivers & Creation of Dissolution Safe Space.
Bhattiprolu AK; Kollipara S; Ahmed T; Boddu R; Chachad S
J Pharm Sci; 2022 Dec; 111(12):3397-3410. PubMed ID: 36096285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
